Although histological studies suggest that predominance of M1-like macrophages, defined by expression of markers such as CD80 and CD86, associates with better outcomes in cancer, the overwhelming evidence suggests that pro-inflammatory cytokines and other inflammatory mediators characteristic of M1 cells are known to contribute to tumour promotion and progression [4,5]. This evidence concerns the gene CD86 and cancer.